2023 Guidance and Q3 Earnings

67 potential new vaccines and medicines in pipeline Phase 23 assets Infectious diseases HIV (ViiV) Respiratory/Immunology Oncology Opportunity driven 4429016 4077164 3943104 3536867 2556286 3186899 3494245 3772701 3882347 3923868 4182137 (VIR-7832) 3965193 5251738 cabotegravir (1265744) 4524184 3888130 3915393 4381562 6097608 XMT-20564 (wholly owned by Mersana Therapeutics) belantamab (2857914) 4524101 4172239 Bioconjugated recombinant protein, adjuvanted* Bivalent GMMA* Recombinant protein, adjuvanted* Bivalent conjugate* Mtb cholesterol dependent inhibitor* CRK-12 inhibitor*2 Proteasome inhibitor* P. falciparum whole cell inhibitor* FimH antagonist* PI4K beta inhibitor Anti-spike protein antibody* PAPD5/PAPD7 inhibitor TLR8 agonist* Integrase inhibitor (400 mg/ml formulation) Integrase inhibitor* Anti-IL7 antibody* TG2 inhibitor* Anti-PVRIG antibody* Anti-CD96 antibody* STING agonist ADC* Anti-BCMA antibody DNA polymerase theta inhibitor* DNMT1 inhibitor* K. pneumoniae Invasive non-typhoidal salmonella** Therapeutic herpes simplex virus' Salmonella (typhoid + paratyphoid A) Tuberculosis Visceral leishmaniasis Visceral leishmaniasis Malaria Uncomplicated UTI Viral COPD exacerbations COVID-191 Hepatitis B virus' Hepatitis B virus HIV HIV Autoimmune disease Pulmonary fibrosis Cancer Cancer Cancer Multiple myeloma Breast cancer¹,3 Sickle cell disease GSK *In-licence or other alliance relationship with third party **Additional indications or candidates also under investigation In registration 1. In phase I/II study 2. Transition activities underway to enable further progression by partner 3. Phase I study start imminent 4. GSK has an exclusive global license option to co-develop and commercialise the candidate 5. GSK has exclusive option to co-develop post phase II 6. Phase II study start imminent 7. Phase III study start expected in 2023 8. Phase III trial in patients with progranulin gene mutation 9. Approved in US 38

View entire presentation